Crossmark

PROMISE international; a clinical post marketing trial investigating the percutaneous deep vein arterialization (LimFlow) in the treatment of no-option chronic limb ischemia patient

Crossref DOI link: https://doi.org/10.1186/s42155-019-0067-z

Published Online: 2019-07-31

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schreve, Michiel A. https://orcid.org/0000-0002-7923-6387
Lichtenberg, Michael

Ünlü, Çagdas

Branzan, Daniela

Schmidt, Andrej

van den Heuvel, Daniel A. F.

Blessing, Erwin

Brodmann, Marianne

Cabane, Vincent

Lin, William Tan Qing

Kum, Steven
License Information

Text and Data Mining valid from 2019-07-31

Version of Record valid from 2019-07-31
More Information

Article History

Received: 11 April 2019

Accepted: 9 July 2019

First Online: 31 July 2019

Ethics approval and consent to participate

: L017–088/ LimFlow Percutaneous, Post Market Study - Protocol version 4, September 13,2018. Start recruitment 29-11-2017, end recruitment 30-12-2019.

: The author(s) declare that they have no competing interests.

Document is current

Any future updates will be listed below